View of Safety and Efficacy of CTX001 in Patients with TransfusionDependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells

Return to Article Details Safety and Efficacy of CTX001 in Patients with TransfusionDependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells Download Download PDF

นโยบายการคุ้มครองข้อมูลส่วนบุคคล Privacy policy